Unknown

Dataset Information

0

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.


ABSTRACT: BACKGROUND:To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS:Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus. Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg. Plasma copanlisib levels were analyzed for pharmacokinetics. Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry. Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects. Plasma glucose and insulin levels were evaluated serially. RESULTS:Fifty-seven patients received treatment. The MTD was 0.8 mg/kg copanlisib. The most frequent treatment-related adverse events were nausea and transient hyperglycemia. Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion. Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%. One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer). Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years. CONCLUSION:Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg. Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL. CLINICALTRIALSGOV:NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.

SUBMITTER: Patnaik A 

PROVIDER: S-EPMC5035790 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A A   Appleman L J LJ   Tolcher A W AW   Papadopoulos K P KP   Beeram M M   Rasco D W DW   Weiss G J GJ   Sachdev J C JC   Chadha M M   Fulk M M   Ejadi S S   Mountz J M JM   Lotze M T MT   Toledo F G S FG   Chu E E   Jeffers M M   Peña C C   Xia C C   Reif S S   Genvresse I I   Ramanathan R K RK  

Annals of oncology : official journal of the European Society for Medical Oncology 20161001 10


<h4>Background</h4>To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).<h4>Patients and methods</h4>Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus. Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the d  ...[more]

Similar Datasets

| S-EPMC5573760 | biostudies-other
| S-EPMC5094563 | biostudies-literature
| S-EPMC4570141 | biostudies-literature
| S-EPMC2997755 | biostudies-literature
| S-EPMC3533660 | biostudies-literature
| S-EPMC4287394 | biostudies-literature
| S-EPMC8462994 | biostudies-literature
| S-EPMC10339701 | biostudies-literature
| S-EPMC2213160 | biostudies-literature
| S-EPMC6288288 | biostudies-literature